This Week in Psychedelics - 12.24.21

Cannabis

• Analysis: Unregulated Delta-8 Vape Products Frequently Mislabeled, May Contain Heavy Metals (NORML)

• Malta Officially Legalizes Marijuana With President’s Signature, Becoming First In Europe To End Cannabis Prohibition (Marijuana Moment)

• Several States to Usher In the New Year with Cannabis Liberalization Laws (NORML)

• The Next States to Legalize Recreational Marijuana (MSN)

• Pfizer Bets On Medical Cannabis With $6.7 Billion Acquisition (Forbes)

• Scientists are (finally) studying how weed affects athletic performance and recovery (Leafly)

• New York Senator Files Bill To Extend Marijuana Equity Benefits To Gay, Lesbian And Bisexual People (Marijuana Moment)

• Cartels Ditch Pot and Opium Fields for Synthetic Drugs, Mexico Defense Secretary Says (High Times)

• Ohio: Citizens’ Petition Seeks to Compel Lawmakers to Hold Marijuana Legalization Vote (NORML)

• Senator Calls For Federal Marijuana Standard To Measure Impaired Driving (Marijuana Moment)

• Top Maryland Lawmaker Files Marijuana Legalization Referendum For 2022 Ballot (Marijuana Moment)

• Iowa Democrats Announce Plan To Let Voters Decide On Marijuana Legalization Amid GOP Resistance (Marijuana Moment)

• Whole-Plant Cannabis Extract Reduces Epileptic Seizures By 86% in Small Study (High Times)

• Researcher Uses Reddit To Learn What Kinds Of Marijuana Posts Influenced Legalization Attitudes (Marijuana Moment)

• Pair of Cops Booked After Being Caught Smoking Pot in Mississippi (High Times)

• Marijuana Group Releases ‘Robbery Preparedness Guide’ For Dispensaries Amid Spike In Thefts (Marijuana Moment)

• Dr. Sanjay Gupta adds to chorus of cannabis research on autism in 2021 (Leafly)

• Legal Cannabis Outsells Ontario Illicit Market for First Time (High Times)

• These were the weirdest weed news stories of 2021 (Leafly)

LSD

• U.S. FDA puts plans to test LSD in anxiety patients in clinical study on hold (Reuters)

Magic Mushrooms

• Canada’s Psilocybin Policy Reform Movement Continues to Make Progress Federally (Truffle Report)

• FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics (Benzinga)

Ayahuasca

• Global ayahuasca trend drives deforestation in Brazil’s Acre state (Mongabay)

Morning Glory Seeds

• Study shows common flower species holds promise for beneficial psychedelic drugs (Newswise)

Ketamine

• Ketamine Therapy Quickly Reduces Depression and Suicidal Thoughts (SciTechDaily)

DXM

• Cough medicine creates dangerous interaction (The Seattle Times)

Miscellaneous

• Port Townsend Becomes 13th City to Decriminalize Psychedelics (DoubleBlind)

• Psychedelics: The newest tool in nuclear negotiations? (Bulletin of the Atomic Scientists)

• How Should Psychedelic Medicine Handle “Flashbacks”? (Mad in America)

• New center to study psychedelics pops up at University of Texas at Austin (My San Antonio)

• The Dumbest Drug Scare Stories of 2021 (VICE)

• DEA Wants To Help Parents Decode The Emojis Young People Use To Discuss Marijuana And Other ‘Bomb Ass’ Drugs (Marijuana Moment)

• GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs (Marijuana Moment)

• Colorado Ballot Initiatives Filed to Legalize Psychedelics (Truffle Report)

• Two Leaders in Psychedelics Industry and the Harm Reduction Approach (Nasdaq)

• How Do Hallucinogenic Drugs Change Our Personality? (Psychology Today)

• Microdosing companion app Houston wants to be your guide to 'inner space' (Mashable)

• Why Psychedelic Research May Bring the Next Big Breakthrough in Dementia Treatment (Psychedelic Spotlight)

• MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Week in Psychedelics - 10.29.21

Cannabis

• With export restrictions eased, Colombia's medical cannabis business is poised for liftoff (CNN)

• Federal Survey Identifies Marked Decline in Youth Marijuana Use (NORML)

• Why did Texas ban Delta-8? (Popular Science)

• Cannabis products may help treat symptoms of depression, improve sleep, and increase quality of life, study suggests (PsyPost)

• California Destroys 1M Plants in Marijuana Eradication Campaign (High Times)

• State Attorneys General Warn About Marijuana-Infused Candy And Snacks Ahead Of Halloween (Marijuana Moment)

• The Myth of Cannabis-Infused Halloween Candy—Debunked (High Times)

• Cannabis is one industry that's actually coming out of Covid even stronger (CNN)

• South Dakota Lawmakers Approve Marijuana Legalization Bill As Activists Pursue 2022 Ballot Initiative (Marijuana Moment)

• New York: Officials Moving to Clear Over 400,000 Past Marijuana Convictions (NORML)

• Montana Supreme Court Unanimously Overturns a Pot Conviction, Saying Cops Stopped the Defendant for No Good Reason (Reason)

• Analysis: ‘Government-Grade’ Marijuana More Closely Resembles Hemp, Has Little in Common with Commercially Available Cannabis (NORML)

• Florida judge rules online marijuana ordering sites may resume business (Marijuana Business Daily)

• Louisiana plans to regulate, not ban, delta-8 THC (Marijuana Business Daily)

• Former Arkansas Lawmaker Launches Campaign To Put Marijuana Legalization On The 2022 Ballot (Marijuana Moment)

• Maryland: Most Residents Want to Legalize Marijuana for Adult Use (NORML)

LSD

• Ex-Denver Cop Who Broke Teen's Face for Dancing on LSD to Cost City $1.2 Million (Westword)

Magic Mushrooms

• Study Finds Psilocybin Improves MDD in Patients With Cancer (Psychiatric Times)

• Latest psilocybin patent highlights the swirling battle over psychedelics intellectual property (STAT)

• Italian Activists Turn In More Than Half A Million Signatures For Marijuana And Psilocybin Referendum (Marijuana Moment)

• Dr. Bronner’s Funds Psilocybin Legalization Effort in Connecticut (High Times)

• More Evidence of the Chemical Compound Variability in Magic Mushrooms (Psychedelic Science Review)

• MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias (Psilocybin Alpha)

• Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome (PR Newswire)

MDMA

• No One Is Wasting Their Ecstasy on Your Kids' Halloween Candy (Reason)

• MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder (Psilocybin Alpha)

Ayahuasca

• Des Moines church fights IRS over ‘religious’ use of hallucinogenic drug (Iowa Capital Dispatch)

5-MeO-DMT

• Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT (Psilocybin Alpha)

Novel Psychoactive Substances

• Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin (Psilocybin Alpha)

• Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease (Psilocybin Alpha)

• Awakn Life Sciences Identifies New Chemical Series Via Its Drug Discovery Program (Awakn Life Sciences)

• Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds (Yahoo! Finance)

Synthetic Cannabinoids

• The Dangers of 'Spice' and Other Synthetic Cannabinoids (Discover Magazine)

Ketamine

• European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders (Psilocybin Alpha)

• Cocaine, ketamine use on the rise: survey (PerthNow)

• Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology (Psilocybin Alpha)

• MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform (Psilocybin Alpha)

Miscellaneous

• Canadian entrepreneur gifts $5 million to help create psychedelic research centre for mental health (CTV News)

• Where the Psychedelic Revolution Is Headed, According to the Guy Who (Arguably) Started It (GQ)

• Psychedelics Group Issues First Round Of Grants For Community-Based Entheogenic Education In DC (Marijuana Moment)

• Addressing Abuse in Psychedelic Spaces (Psychedelics Today)

• North America Continues Leading The Way In Psychedelic Wellness (PR Newswire)

• Psychedelic Patents Should Be Limited, Harvard Law Experts Say (Psychedelic Spotlight)

• Could Psychedelics Cure Our Post-Pandemic Depression? (Truffle Report)

• How Gender Affects the Way We Use Drugs (TalkingDrugs)

• DC Voters Strongly Support Drug Decriminalization, Poll Finds As Activists Launch Campaign (Marijuana Moment)

• MAPS Canada’s Data Breach Foreshadows Corporadelic Future (Psymposia)

• Wavepaths: The Neuroscientist-Founded Company Producing Music For—And As—Psychedelic Therapy (Forbes)

• Novamind Brings Contract Research To Psychedelic Medicine (Lucid News)

• Psychedelic Research Beyond Depression & Trauma (Truffle Report)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

This Week in Psychedelics - 10.22.21

Cannabis

• Luxembourg first in Europe to legalise growing and using cannabis (The Guardian)

• Switzerland to legalise recreational and medical cannabis usage (The Local)

• Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer (Marijuana Moment)

• New York: Employers Are Prohibited from Testing Most Employees for Cannabis (NORML)

• Top Mexican Senator Says Marijuana Legalization Bill May Be Taken Up Within Weeks (Marijuana Moment)

• South Dakota Lawmakers Advance Marijuana Legalization Bill As Activists Pursue 2022 Ballot Initiative (Marijuana Moment)

• Oregon illegal pot grows: More calls to send National Guard (AP News)

• USPS Releases Final Rule Banning Mailing Of Hemp, CBD And Marijuana Vapes (Marijuana Moment)

• Alabama Announces Medical Cannabis Licenses Won’t Be Available Until 2022 (High Times)

• Impact Of Marijuana Legalization On Crime Reduction Is Being Underestimated, New Study Finds (Marijuana Moment)

• Recreational Cannabis Law in Washington, D.C. May Soon Be Operational (High Times)

• New York: Officials Advance Home Cultivation Regulations for Qualified Patients (NORML)

• Minnesota Denies Coverage of Medical Marijuana for Injured Workers (High Times)

• Brit jailed for 25 years in Dubai over CBD vape oil speaks of 'shocking' conditions in call to mum (ITV)

• Indica and Sativa Labels Can’t Be Trusted, Study Indicates (High Times)

• Americans Want To Live Where Marijuana Is Legal, Real Estate Survey Finds (Marijuana Moment)

• Study: Cannabis Use Benefits ADHD Symptoms in Adults, According to Self-Reports (ADDitude)

LSD

• LSD vs. Psilocybin Microdosing for Mental Health and Workplace productivity (The Third Wave)

• Can You Overdose On LSD? This Is What To Know (Healing Maps)

Magic Mushrooms

• Boris Johnson to consider calls to legalise magic mushroom drug psilocybin (BBC)

• Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups (Psilocybin Alpha)

• COMPASS Pathways is granted new US patent for crystalline psilocybin (Psilocybin Alpha)

• Doing Shrooms Alone: The Art of Tripping Solo (DoubleBlind)

• Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation (Psilocybin Alpha)

• The “Unsung History” of Psilocybin Research: Gastón Guzmán and His Scientific Contribution (Chacruna)

• Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product (Psilocybin Alpha)

• Magic Mushrooms Could One Day Treat Depression. How Do They Work? (ScienceAlert)

MDMA

• Treating Hypoactive Sexual Disorder With MDMA (Reality Sandwich)

DMT

• First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial (Psilocybin Alpha)

• Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder (Psilocybin Alpha)

Novel Psychoactive Substances

• Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies (Psilocybin Alpha)

• Emyria passes MDMA analogue development milestone with Eurofins to lead extensive compound screening program (Proactive Investors)

Nitrous Oxide

• Nang gang: Nitrous oxide helps alleviate depression, study finds (The Big Smoke)

Ketamine

• Are Ketamine Clinics Paving the Way for Legal Psychedelic Therapy? (DoubleBlind)

• Why Ketamine-Assisted Therapy Has Gone Mainstream (Forbes)

• PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products (Psilocybin Alpha)

Miscellaneous

• Easthampton, Mass. Decriminalizes Natural Psychedelics (DoubleBlind)

• Oakland Psychedelics Activists Launch Initiative To Legalize Community-Based Sales With Support From City Council (Marijuana Moment)

• DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone (Marijuana Moment)

• Preventing Sexual Abuse in Psychedelic Therapy (Psychedelic Spotlight)

• Bank Of America Cancels Account Of Marijuana And Psychedelics Research Institute Registered With DEA (Marijuana Moment)

• Activist Apes Erect 2,001-Pound Monolith In Front Of DEA Headquarters, Demanding Feds ‘Evolve’ On Drug Policy (Marijuana Moment)

• How Do I Talk To My Doctor About Psychedelics? (Truffle Report)

• Addressing Abuse and Repair: An Open Letter to the Psychedelic Community (Chacruna)

• This New Company Believes Psychedelics Can Treat Dementia (Psychedelic Spotlight)

• Campaign Launches to Decriminalize Drugs in Washington, DC (Filter)

• Can microdosing psychedelics impact an insurance application? (News24)

• Even in a Year of Massive Reforms, Racist Myths Pervade the Drug Policy Debate (TalkingDrugs)

• Countdown to ecstasy: how music is being used in healing psychedelic trips (The Guardian)

• Homecoming: The Psychedelic Digital Companion Therapists Are Already Using (Forbes)

• The Whitewashing of Psychedelic Medicine (Reality Sandwich)

• Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton (Psilocybin Alpha)

• Baltimore Study Boosts Movements to Decriminalize Drugs and Sex Work (Filter)

• Carlos Santana still takes hallucinogens (MSN)

• ‘Shrooms! Shamans! Kosher LSD! Why Los Angeles Is Suddenly Tripping Out (Los Angeles Magazine)

• How Nutrition Can Improve the Psychedelic Experience (Psychedelic Spotlight)

• Why creatives should microdose LSD and cannabis before big pitches (AdAge)

• Psychedelics and Sports: Can They Propel Athletes to Unprecedented Pinnacles of Ability? (Psychedelic Spotlight)

• Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders (Psilocybin Alpha)

• The Neuroanatomy of a Psychedelic Trip: The Basics (Healing Maps)

• atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.